It has been an ugly day for the markets in the past few days. The biotech sector has been particularly hard hit.
2014 has been an eventful year on Wall Street. Now that the year is coming to an end, what stocks should investors be …
In a research report issued today, William Blair analyst Y. Katherine Xu maintained an Outperform rating on Chimerix (NASDAQ:CMRX) with a price target of …
In a research report issued today, Brean Capital analyst Jonathan Aschoff assigned a Buy rating on Chimerix (NASDAQ:CMRX) with a price target of …
In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix (NASDAQ:CMRX) with a $33 price target, as preliminary data from …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Chimerix (NASDAQ:CMRX) with a price target of …
